Vaccibody’s proprietary, targeted vaccine platform centers around the ability to induce a fast, strong and long-lasting specific immune response.
The recombinant Vaccibody protein consists of three modules:
The Vaccibody vaccine is delivered as a DNA plasmid using a needle-free jet injector that injects the plasmids which are subsequently taken up into the patient’s muscle cells. Inside the cells, the DNA plasmids provide the information to start producing the Vaccibody protein in the same way that cells produce other human proteins. The newly encoded Vaccibody proteins are then secreted from the cells, and target and deliver their antigens to the APC. The selected targeting unit determines the delivery of the antigen to specific subsets of APC, which ultimately affects the kinetics and immune response profile. The MIP-1α targeting unit used in Vaccibody’s two clinical products has been selected due to its ability to attract APC and induce rapid, strong and dominant CD8 killer T cell responses. The unique ability to induce a strong CD8 killer T cell response has been shown to be important for tumor cell killing and distinguishes the Vaccibody platform from both conventional vaccines, including non-targeted DNA vaccines, and RNA- and peptide-based vaccines.
The Vaccibody vaccine has demonstrated a favorable safety profile and has the potential to be used in a number of different disease areas, including cancer and infectious diseases. It can be optimized for each disease by matching the antigen of choice with a targeting unit providing an immune response profile correlating with protection.
The Vaccibody vaccine may be:
Off-the-shelf: An off-the-shelf (ready-made) vaccine that encodes for antigens shared among a large patient population, such as the VB10.16 vaccine that targets all HPV16-positive cancers.
Personalized: The antigens may be selected from the individual patient’s tumor, and a fully personalized vaccine is produced matching the optimal set of antigens identified in the tumor. Vaccibody’s VB10.NEO program is such a fully personalized vaccine, targeting the patient’s antigens based on tumor-specific mutations (i.e. distinctly non-self), so-called neoantigens.
The process and supply chain to produce an off-the-shelf vaccine has become a standard process in the industry. A fully personalized vaccine on the other hand is a much more complex process and requires a rapid turnaround time and robust processes across the entire value chain. Experience from the VB N-01 clinical trial testing VB10.NEO indicates that Vaccibody has a competitive advantage in the manufacturing process with a 100% success rate so far (i.e., all patients received a vaccine).
The unique mechanism of action leading to rapid, strong and CD8-dominating responses has also led to highly encouraging immunological and clinical signs of efficacy in the first patients evaluated.